Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ.

Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2. Epub 2010 Mar 5.

PMID:
20204499
2.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
3.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
4.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

PMID:
18159035
5.

Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ.

J Natl Cancer Inst. 2012 Jul 18;104(14):1068-79. doi: 10.1093/jnci/djs261. Epub 2012 Jul 5. Review.

PMID:
22767204
6.

Breast cancer and microRNAs: therapeutic impact.

Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E.

Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1. Review.

PMID:
22015296
7.

Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.

Abu-Khalf M, Pusztai L.

Breast. 2013 Aug;22 Suppl 2:S83-7. doi: 10.1016/j.breast.2013.07.015. Review.

PMID:
24074799
8.

Developments in the systemic treatment of endometrial cancer.

Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, Dimopoulos MA, Papadimitriou CA.

Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92. doi: 10.1016/j.critrevonc.2010.07.013. Epub 2010 Sep 15. Review.

PMID:
20833559
9.

Tailoring adjuvant treatments for the individual patient with luminal breast cancer.

Munzone E, Curigliano G, Colleoni M.

Hematol Oncol Clin North Am. 2013 Aug;27(4):703-14, vii-viii. doi: 10.1016/j.hoc.2013.05.012. Epub 2013 Jun 18. Review.

PMID:
23915740
10.

[Gene expression classifiers in the prognosis of breast cancer].

Drukker CA, Schmidt MK, van Dalen T, van der Hoeven JJ, Linn SC, Rutgers EJ.

Ned Tijdschr Geneeskd. 2014;158:A7001. Review. Dutch.

PMID:
24780571
11.

[Report on the NIH Consensus Development Conference on Adjuvant Therapy of Breast Carcinoma].

Kaufmann M, von Minckwitz G.

Onkologie. 2001 Apr;24(2):190-2. Review. German. No abstract available.

PMID:
11441303
12.

Optimizing chemotherapy regimens for patients with early-stage breast cancer.

Dotan E, Goldstein LJ.

Clin Breast Cancer. 2010;10 Suppl 1:E8-15. doi: 10.3816/CBC.2010.s.002. Review.

PMID:
20587409
13.

[Treatment guideline for advanced or recurrent breast cancer].

Watanabe T, Katsumata N, Saijo N.

Nihon Rinsho. 2000 Apr;58 Suppl:237-45. Review. Japanese. No abstract available.

PMID:
11026001
14.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

15.

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.

Carlson JJ, Roth JA.

Breast Cancer Res Treat. 2013 Aug;141(1):13-22. doi: 10.1007/s10549-013-2666-z. Epub 2013 Aug 24. Review. Erratum in: Breast Cancer Res Treat. 2014 Jul;146(1):233.

16.

SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.

Del Barco S, Ciruelos E, Tusquets I, Ruiz M, Barnadas A; SEOM..

Clin Transl Oncol. 2013 Dec;15(12):1011-7. doi: 10.1007/s12094-013-1084-3. Epub 2013 Aug 27. Review.

PMID:
23979909
17.

Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.

Markopoulos C.

Expert Rev Anticancer Ther. 2013 Feb;13(2):179-94. doi: 10.1586/era.12.174. Review.

PMID:
23406559
18.

Breast cancer assessment tools and optimizing adjuvant therapy.

Oakman C, Santarpia L, Di Leo A.

Nat Rev Clin Oncol. 2010 Dec;7(12):725-32. doi: 10.1038/nrclinonc.2010.170. Epub 2010 Oct 26. Review.

PMID:
20975745
19.

The present and future of gene profiling in breast cancer.

Espinosa E, Gámez-Pozo A, Sánchez-Navarro I, Pinto A, Castañeda CA, Ciruelos E, Feliu J, Vara JA.

Cancer Metastasis Rev. 2012 Jun;31(1-2):41-6. doi: 10.1007/s10555-011-9327-7. Review.

PMID:
22124734
20.

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members..

Ann Oncol. 2005 Oct;16(10):1569-83. Epub 2005 Sep 7.

PMID:
16148022

Supplemental Content

Support Center